Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy

Japanese Journal of Clinical Oncology

Volumn 40, Issue 4, 2010, Pages 353-359

  Komaru, Atsushi ^a   Kamiya, Naoto ^a   Suzuki, Hiroyoshi ^a   Endo, Takumi ^a   Takano, Makoto ^a   Yano, Masashi ^a   Kawamura, Koji ^a   Imamoto, Takashi ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Body mass index; Hyperlipidemia; Obesity; Prostate cancer; Prostatectomy

Indexed keywords

CHOLESTEROL; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANTIGEN DETECTION; ARTICLE; BLEEDING; BODY MASS; CANCER RECURRENCE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; HYPERLIPIDEMIA; JAPANESE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; TESTOSTERONE BLOOD LEVEL; ASIAN; BLOOD; CANCER STAGING; KAPLAN MEIER METHOD; OBESITY; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; DISEASE-FREE SURVIVAL; HUMANS; HYPERLIPIDEMIAS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77951235701     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp164     Document Type: Article

References (40)

1. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996;14:12-20.
2. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
3. Andersson SO, Wolk A, Bergström R, Adami HO, Engholm G, Englund A, et al. Body size and prostate cancer: a 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
4. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in The Netherlands Cohort Study. Am J Epidemiol 2000;151:541-9.
5. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. JAMA 2002;288:1723-7.
6. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45.
7. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53.
8. Hisasue S, Yanase M, Shindo T, Iwaki H, Fukuta F, Nishida S, et al. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy. Jpn J Clin Oncol 2008;38:129-33.
9. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999;91:414-28.
10. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004;93:1139-50.
11. Platz EA. Energy imbalance and prostate cancer. J Nutr 2002;132:3471-81.
12. Isom-Batz G, Bianco FJ, Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935-7.
13. Lunenfeld B. Testosterone deficiency and the metabolic syndrome. Aging Male 2007;10:53-6.
14. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005;47:308-12.
15. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
16. Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998;56:106-14.
17. Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: The National Nutrition Survey 1976-95. Obes Rev 2002;3:183-90.
18. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
19. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
20. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005;174:919-22.
21. Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 2005;11:2883-8.
22. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005;174:1798-801.
23. Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, et al. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology 2007;70:1146-51.
24. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, et al. Leptin and prostate cancer. Prostate 2001;46: 62-7.
25. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Söderberg S, Olsson T, et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003;12:309-15.
26. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007;16:308-13.
27. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7.
28. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670-5.
29. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, et al. Plasma-free and non-sex-hormone binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929-31.
30. Morales A, Lunenfeld B. Investigation, treatment, monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5:74-86.
31. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005;174:1266-70.
32. Sher D, Oh W, Jacobus S, Regan MM, Lee G, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008;68:1592-8.
33. Wabitsch M, Blum WF, Muche R, Braun M, Hube F, Rascher W, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest 1997;100:808-13.
34. Isidori A, Caprio M, Strollo F, Moretti C, Frajese G, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-80.
35. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
36. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008;19:1259-66.
37. Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 2006;17:1014-7.
38. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
39. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008;123:899-904.
40. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004;13:47-55